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•		Response	following	positive	sterility	test	results		
	 	 –		Notified providers
	 	 	 	 •		Disclosed event to patients (5)
	 	 	 	 •		Contacted Risk Management
	 	 –		Retrieved unused syringes  
	 	 –		Sterility tested more syringes from batch
	 	 –		Screened patients (blood 
cultures negative)
	 	 –		Risk Management 
engaged:
	 	 	 	 •		Infection Control
	 	 	 	 •		Microbiology Lab
	 	 	 	 •		Pharmacy
	 	 	 	 •		Infectious Diseases
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	 	 –		Prepared in the pharmacy clean room
	 	 –		Given a 9 day beyond use date (BUD)
	 	 –		Sterility tested
	 	 –		Released to stock
























	 	 –		Reviewed USP 797 and USP 71 Guidelines with all stakeholders
	 	 –		Re-educated pharmacy staff with infection prevention strategies
	 	 	 	 •		Aseptic technique
	 	 	 	 •		Personal Protective Equipment
	 	 	 	 •		Traffic control
	 	 	 	 •		Hand hygiene
	 	 	 	 •		Excessive talking 
	 	 –		Improved environmental air sampling procedure:
	 	 	 	 •		Monthly settling plate sampling → monthly volumetric sampling






	 	 –		Released without quarantining
	 	 –		Notification to Pharmacy Management, Infection Control and Risk 
Management if any products that tested positive reached patients  
	 	 –		Further dissemination of information to additional stakeholders
•		Products	that	get	sterility	tested	based	on	USP	797	guidelines
	 	 –		Quarantine period
	 	 –		Notification to Pharmacy Management and Infection Control, but not Risk 
Management if no products dispensed to patients
	 	 –		Pharmacy will then consult with Infection Control to investigate possible 
causes 
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